Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M-M Samama

Showing results (21-30 of 184) with videos related to

Pageof 19
Sort By:
Archives Des Maladies Du Coeur Et Des Vaisseaux|June 1, 1996
[Activated protein C resistance and mutation of coagulation factor V]M M Samama
Journal Des Maladies Vasculaires|July 2, 2004
[Ximelagatran/Melagatran. Perspectives for new oral antithrombin drugs]M M Samama
Revue Medicale De La Suisse Romande|April 1, 1995
[Characteristics of the diagnosis and treatment of venous thrombosis. Benefit-risk relationship of anticoagulant treatment]M M Samama
Journal Des Maladies Vasculaires|June 3, 2008
[New large-scale studies with idraparinux, a prolonged action anticoagulant active via parenteral administration]M-M Samama
Archives Des Maladies Du Coeur Et Des Vaisseaux|November 1, 1995
[Study of hemostasis in patients with a recent thromboembolic complication]M M Samama
Presse Medicale (Paris, France : 1983)|December 9, 1995
[New antithrombotic agents]A Keréveur, M M Samama
Journal Des Maladies Vasculaires|January 18, 2011
[Direct inhibitors of thrombin, hirudin, bivalirudin, and dabigatran etexilate]S Meddahi, M M Samama
Annales De Biologie Clinique|June 10, 2000
[Heparin-induced thrombocytopenia]F Depasse, M M Samama
Journal of Thrombosis and Haemostasis : JTH|March 8, 2005
Primary and secondary prophylaxis of venous thromboembolism with low-molecular-weight heparins: prolonged thromboprophylaxis, an alternative to vitamin K antagonistsA Kher, M M Samama
Annales Pharmaceutiques Francaises|April 4, 2007
[New antitoagulants]M-M Samama, G Gerotziafas
Pageof 19

Showing results (21-30 of 184) with videos related to

Sort By:
Pageof 19
Archives Des Maladies Du Coeur Et Des Vaisseaux|June 1, 1996
[Activated protein C resistance and mutation of coagulation factor V]M M Samama
Journal Des Maladies Vasculaires|July 2, 2004
[Ximelagatran/Melagatran. Perspectives for new oral antithrombin drugs]M M Samama
Revue Medicale De La Suisse Romande|April 1, 1995
[Characteristics of the diagnosis and treatment of venous thrombosis. Benefit-risk relationship of anticoagulant treatment]M M Samama
Journal Des Maladies Vasculaires|June 3, 2008
[New large-scale studies with idraparinux, a prolonged action anticoagulant active via parenteral administration]M-M Samama
Archives Des Maladies Du Coeur Et Des Vaisseaux|November 1, 1995
[Study of hemostasis in patients with a recent thromboembolic complication]M M Samama
Presse Medicale (Paris, France : 1983)|December 9, 1995
[New antithrombotic agents]A Keréveur, M M Samama
Journal Des Maladies Vasculaires|January 18, 2011
[Direct inhibitors of thrombin, hirudin, bivalirudin, and dabigatran etexilate]S Meddahi, M M Samama
Annales De Biologie Clinique|June 10, 2000
[Heparin-induced thrombocytopenia]F Depasse, M M Samama
Journal of Thrombosis and Haemostasis : JTH|March 8, 2005
Primary and secondary prophylaxis of venous thromboembolism with low-molecular-weight heparins: prolonged thromboprophylaxis, an alternative to vitamin K antagonistsA Kher, M M Samama
Annales Pharmaceutiques Francaises|April 4, 2007
[New antitoagulants]M-M Samama, G Gerotziafas
Pageof 19